AVECHO BIOTECHNOLOGY LIMITED — Share Issue/Capital Change 2021

Jun 30, 2021

==> picture [77 x 35] intentionally omitted <==

==> picture [24 x 26] intentionally omitted <==

==> picture [22 x 35] intentionally omitted <==

==> picture [26 x 26] intentionally omitted <==

ASX Announcement

1 July 2021

ASX Market Announcements ASX Limited Level 4, North Tower, Rialto 525 Collins Street Melbourne VIC 3000

Section 708A Cleansing Notice and Appendix 2A

Melbourne , Australia, 1 July 2021 – This notice is given by Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), under Section 708A(5)(e) of the Corporations Act 2001 (Cth)(“Corporations Act”).

The Company hereby confirms that:

• (a) it has issued a total of 7,221,847 Fully Paid Ordinary Shares (Shares) for nil consideration following the vesting of 7,221,847 unlisted Performance Rights on 1 July 2021

• (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

• (c) it is providing this notice under paragraph 5(e) of Section 708A of the Corporations Act;

• (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

  • (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • (ii) Section 674 of the Corporations Act as it applies to the Company; and

• (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

An Appendix 2A lodged relating to the issue of shares noted above is attached.

For enquiries, please contact

Ms Melanie Leydin Company Secretary Avecho Biotechnology Limited +61 3 9002 5000

About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture ( TPM® ). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - avecho.com.au

Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168

avecho.com.au